Medtronic Raises 2027 Forecasts Amid Heart Device Demand Surge

Medtronic has raised its fiscal 2027 revenue growth and profit forecasts, driven by a rising demand for heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from an earlier projection of 6.75% to 7.25%. The lower end of its adjusted per-share profit forecast has been lifted to $5.94 from $5.90, although the upper limit remains at $6.

CEO Geoff Martha attributed the optimistic outlook not only to the strength observed in the recent quarter but also to a broad performance across its business units and contributions from new growth platforms. During a post-earnings call, Martha emphasized the company's strategic focus on high-growth segments with large patient pools.

Strategic Investments and Market Expansion

In a move to bolster its market position, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the U.S. Martha noted the complementary nature of Cornerstone’s Sentire device to Medtronic's existing Hugo system, especially in emerging markets where soft tissue robotic surgery penetration is below 1%.

Cardiovascular Segment Drives Growth

The company's cardiovascular segment reported a significant 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely fueled by an 88% surge in its pulsed field ablation portfolio, which is utilized to treat irregular heart rhythms. Medtronic's financial results exceeded market expectations, with an adjusted quarterly per-share profit of $1.45 and revenue totaling $9.76 billion, surpassing estimates of $1.39 profit on $9.55 billion in sales, according to LSEG-compiled data.

Medtronic's finance chief Thierry Pieton mentioned that the company received tariff refunds that nearly offset the duties paid during the quarter. However, these refunds have not been factored into future financial outlooks.

As Medtronic continues to expand its footprint in the medtech industry, its strategic investments and focus on high-potential markets are expected to drive further growth, positioning the company to capitalize on emerging opportunities in the global healthcare landscape.